EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: A cross-sectional study

Jaishree Mendiratta, Ravi N Vaswani, Gayatri Saberwal iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0284434 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Jaishree Mendiratta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City Phase 1, Bengaluru, Karnataka, India. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Electronics, IT, BT and S&T, Government of Karnataka.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In multinational trials that have run in India, we wished to determine whether there was too much (60% or higher) recruitment from India. We downloaded all trial records from Clinical Trials Registry-India, CTRI, and stored them in a local SQLite database. We queried records registered in a recent 8-year period, ie 2013–2020 and evaluated the fraction of local participants in interventional Phase 2 or Phase 3 studies. 62 trials were completed, with completion dates available. Five trials (8%) had 60% or more planned recruitment from India. Four of the five (7% of 62) had a foreign sponsor, and therefore there was an unfair burden-benefit ratio on the Indian population. Seven trials (11%), of which six (10% of 62) had foreign sponsors, had 60% or more (of the total) actual recruitment from India, and for two trials (both with foreign sponsors), the data were meaningless. There were 362 studies that were listed as not completed, although, given their start date and estimated duration, some of them ought to have been. Twenty five cases (7% of 362) had 60% or more planned recruitment from India. Of these, 18 (5% of 362) had foreign sponsors and were potentially problematic. Even allowing for some delays in completion, 128 (35% of 362) studies ought to have been completed by the time of our study. As such, we identified several problematic trials for which the planned recruitment from India in multinational studies was 60% or more. We also identified trials in which the actual recruitment was significantly higher than the planned recruitment. Further, the records of several studies that were probably completed were not updated in CTRI in a timely manner. The Indian drug regulator needs to be particularly alert to the planned , or actual , over-recruitment of participants from India. Further, CTRI, alone or in collaboration with the regulator, needs to ensure that multinational trial records for the enrollment fields in particular are updated, in a timely manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicHumansCross-Sectional StudiesDatabases, FactualIndiaRegistries

Autor:innen und Institutionen

  • Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City Phase 1, Bengaluru, Karnataka, India.
  • Yenepoya Deemed to be University, University Road Deralakatte, Mangaluru, Karnataka, India.

ORCID-Profile: Gayatri Saberwal

Förderung

  • Department of Electronics, IT, BT and S&T, Government of Karnataka

Zitieren

APA

Mendiratta, J., Vaswani, R. N., & Saberwal, G. (2023). Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: A cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0284434

Vancouver

Mendiratta J, Vaswani RN, Saberwal G. Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: A cross-sectional study. PLOS ONE. 2023. doi:10.1371/journal.pone.0284434

BibTeX
@article{Mendiratta2023,
  author = {Mendiratta, Jaishree and Vaswani, Ravi N and Saberwal, Gayatri},
  title = {Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: A cross-sectional study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0284434}
}
Kostenlos starten →